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a b s t r a c t
A speciﬁc and reliable HPLC–MS/MS method was developed and validated for the determination of ara-U
in human plasma. The analyte was separated on a C18 column (50mm×2.1mm, 1.7m) and a triple-
quadrupole mass spectrometry equipped with an electrospray ionization (ESI) source was applied for
detection. Theplasma samplewaspreparedbya simpleproteinprecipitationpretreatment and the recov-vailable online 26 July 2013
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ery was about 80%. The calibration curves were linear over a concentration range of 1.0–7000.0ng/mL
for ara-U. The intra-day and inter-day precision was less than 15% and the relative error (RE) was all
within ±15%. It was successfully applied to assess the disposition characteristics of ara-U and support
the therapeutic drug monitoring after the patients with leukemia were infused with ara-C.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.
uman plasma
. Introduction
1--d-Arabinofuranosylcytosine (ara-C, cytarabine) was a
yrimidine nucleoside analog widely employed for the treat-
ent of both acute and chronic myeloblastic leukemias [1,2].
--d-Arabinofuranosyluracil (ara-U, uridine) was a nontoxic
eamination product of 1--d-arabinofuranosylcytosine in vivo.
ra-C was metabolized to the nucleotide monophosphate, ara-
MP, by deoxycytidine kinase (dCyd kinase), then to the nucleotide
riphosphate, ara-CTP, to exert its cytotoxic effect. In the clini-
al therapy, the multiple intravenous infusion of high dose ara-C
HiDAC) was routinely applied to reinduce remission in patients
ho fail induction or who relapse while being treated with
egimens that include conventional doses of ara-C. This kind of reg-
men was based on the following mechanism that high levels of
∗ Corresponding author. Tel.: +86 791 83969510; fax: +86 791 83969069.
E-mail address: liaochuanrong@hotmail.com (C. Liao).
1 Both these authors contributed equally to this paper.
731-7085 © 2013 The Authors. Published by Elsevier B.V.
ttp://dx.doi.org/10.1016/j.jpba.2013.07.015
Open access under CC BY-NC-N1--d-arabinofuranosyluracil (Hiara-U), which was from the
metabolism of HiDAC, can prolong the S phase of the cell cycle and
increase the activity of dCyd kinase, thus resulted in enhancement
in anabolism and cytotoxicity of ara-C in vivo [3–5]. Because the
concentration of ara-U in vivo can affect the therapeutic effect of
ara-C, it was imperative to develop a simple and sensitive method
to determine ara-U in plasma to study the disposition character-
istics of ara-U and support the therapeutic drug monitoring when
HiDAC was repeatedly infused to the patient.
The quantiﬁcation of ara-U in the biological samples has
attracted attention since the endof 1970s.High-performance liquid
chromatography/ultraviolet method (HPLC/UV) has been reported
for the determination of ara-U in human and rodent plasma [6,7].
However, these methods were not very sensitive and required
long time analysis. Up to date, only one paper described a liquid
chromatography–tandemmass spectrometry (LC–MS/MS)method
to determine the concentration of ara-U in rat plasma [8]. However,
this article lacked complete validation data and did not provide any
chromatogram. In the present study, a facile LC–MS/MS method
was developed and validated to determine ara-U in human plasma
for the ﬁrst time. The results showed this method was selective,
sensitive and accurate to measure ara-U in plasma. The lower limit
of quantiﬁcation (LLOQ) was 1ng/mL with only 30L plasma used.
D license.
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he sample was pretreated with a simple protein precipitation
rocedure. At present, the simultaneous determination of ara-U
nd ara-C in plasma by LC–MS/MS has not been reported, and
he present article also provided the validation procedure for the
C–MS/MS determination of ara-C. Finally, the method was suc-
essfully applied to assess the disposition characteristics of ara-U
ndsupport the therapeuticdrugmonitoringafter thepatientswith
eukemia were intravenously infused with HiDAC repeatedly.
. Experimental
.1. Chemicals and reagents
Ara-U (>99.5% purity) was purchased from Xinxiang Pharm
orp. (Xinxiang, China). Ara-C was purchased from Surui Pharm
orp. (Suzhou, China). Isoniazid and lamivudine (internal standard,
S >99.5% purity) was purchased from the National Institute
or the Control of Pharmaceutical and Biological Products (Bei-
ing, China). The injection of ara-C was provided by Haizheng
harm Corp. (Taizhou, China). Waters Oasis MCX cation exchange
olid-phase extraction cartridges (1 cc/30mg) were obtained from
aters Corporation (Milford, MA, USA). Tetrahydrouridine (THU),
he deaminase inhibitor, was purchased from Calbiochem (La Jolla,
A, USA). Methanol and acetonitrile (HPLC-grade) was purchased
rom Fisher Scientiﬁc (Pittsburgh, PA, USA). Ultrapure water was
repared by EASYPUREIIRF/UV system (Boston, MA, USA).
.2. Instrumentation
A Waters ACQUITY TQD system was employed for the deter-
ination of the analytes, which consisted of an ACQUITY UPLC
ystem and an ACQUITY triple-quadrupole tandem mass spec-
rometry with an electrospray ionization (ESI) interface (Waters
orp., Milford, MA, USA). An ACQUITY UPLC BEH C18 column
50mm×2.1mm, 1.7m, Waters Corp., Milford, MA, USA) was
sed to separate the analytes. All datawere acquired and processed
sing MassLynx 4.1 software with QuanLynx.
.3. HPLC–MS/MS condition
In the present study, two different HPLC–MS/MS methods were
eveloped to determine the concentration of ara-U and ara-C in
uman plasma, respectively.
The following gradient elution was conducted for ara-U with
he mobile phase A (water), and the mobile phase B (acetonitrile)
s follows: 0 (100% A), 1.5min (100% A), 3.0min (70% A), 3.01min
100% A) and 5.0min (100% A) and ﬁnished at 5min. The following
radient elution was conducted for ara-C with the mobile phase
(methanol containing 0.1% formic acid), and the mobile phase
(water–methanol, 98:2, v/v) as follows: 0 (0% A), 3.0min (30%
), 3.01min (0% A) and 5.0min (0% A) and ﬁnished at 5min. The
ow rate was 0.2mL/min and the column temperature was 40 ◦C.
njection wash solvents were acetonitrile–water (5:95, v/v) and
cetonitrile–water (95:5, v/v) for weak and strong wash, respec-
ively.
For MS detection, positive ESI was used as the ionization mode.
itrogen was used as the desolvation and cone gas with a ﬂow
ate of 500 and 50L/h, respectively. The optimal MS parameters for
ra-U and isoniazid were as follows: capillary 2.5 kV, source tem-
erature 110 ◦C and desolvation temperature 380 ◦C. Cone voltage
as 25 and 20V for ara-U and isoniazid, respectively. The posi-ive multiple reaction monitoring was used for the quantiﬁcation.
he transitions of m/z 245.1→113.2 with collision energy (CE) of
6 eV and m/z 137.9→120.9 with CE of 15eV were used for the
uantiﬁcation of ara-U and isoniazid, respectively (Fig. 1).Fig. 1. Product ion mass spectra of [M+H]+ ion of ara-U (A), isoniazid (B), ara-C (C)
and lamivudine (D).
The optimal MS parameters below were for ara-C and lamivu-
dine: capillary 2.8 kV, source temperature 110 ◦C and desolvation
temperature 380 ◦C. Cone voltage was 26 and 19V for ara-C and
lamivudine, respectively. The transitions ofm/z 244.1→112.0with
collision energy (CE) of 25 eV and m/z 230.2→112.2 with CE of
17eV were used for the quantiﬁcation of ara-C and lamivudine,
respectively (Fig. 1). The dwell time was 0.1 s.
2.4. Preparation of standard and quality control samplesThe standard stock solution of ara-U (14.0g/mL) and ara-C
(10.0g/mL) were prepared with water, respectively. Then, the
solutionwas serially diluted to provideworking standard solutions
of the desired concentrations. The concentrations of the internal
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tandard solution were 4000.0ng/mL (isoniazid) and 1000.0ng/mL
lamivudine).
The calibration curve for ara-Uwas prepared by spiking 30L of
lankhumanplasmawith 30-L of ara-U standard solution and30-
L of internal standard solution (isoniazid). The calibration curve
or ara-C was prepared by spiking 30L of blank human plasma
ontaining THU (0.1mM)with 30L of ara-C standard solution and
0L of internal standard solution (lamivudine). The quality con-
rol (QCs) samples at low, medium and high concentration levels
ere prepared in the sameways as the calibration curves. Thenom-
nal plasma concentrations of QC samples were 2.0, 3500.0, and
000.0ng/mL for ara-U, and 10.0, 2500.0, 4000.0ng/mL for ara-C.
.5. Sample preparation
To determine ara-U, plasma samples were diluted 10 times
ith blank human plasma before pretreatment if the concentra-
ion was over the range of the calibration curve. Then, to a 30-L
liquot of diluted plasma sample, 30L of internal standard solu-
ion (isoniazid, 4000.0ng/mL) and 30L water were added. After
he addition of 200L acetonitrile, the sample was brieﬂy mixed
nd centrifuged at 2500× g and 4 ◦C for 10min. The supernatant
as transferred to an autosampler vial and injected (5L) to the
C–MS/MS system at 4 ◦C for analysis.
To determine ara-C, 20L of internal standard solution
1000.0ng/mL, lamivudine) and 30-L water were added to 30L
liquot of plasma sample. The sample was brieﬂy mixed following
he addition of 400L water and then centrifuged at 2500× g and
◦C for 5min. The supernatant was transferred to a solid-phase
xtraction cartridge which was pre-equilibrated by washing with
mL methanol and then 1mLwater before use. The samples were
ashed by 1mL of 0.05M hydrochloric acid solution containing 5%
ethanol twice and then by 1mL of methanol. Ara-C was eluted
ith 1mL of ammonium hydroxide in methanol (5:95, v/v) twice.
he eluateswere evaporated to dryness under nitrogen at 37 ◦C and
hen reconstituted in 300L ofwater by vortexmixing (1min). The
esulting solution was transferred to an autosampler vial at 4 ◦C,
nd injected (5L) into HPLC/MS/MS system.
.6. Method validation
The validation of the above method was carried out as US FDA
uidelines, including selectivity, linearity, precision and accuracy,
ecovery, matrix effect, and stability [9].
Selectivity was assessed by comparing chromatograms of six
ifferent batches of blank plasma with the corresponding spiked
lasma at LLOQ level. The peak area of the co-eluting components
hould be less than 20% and 5% those of the analyte and the corre-
ponding IS, respectively.
The LLOQ, deﬁned as the lowest concentration on the calibra-
ion curve, was evaluated by analyzing the samples prepared in
ix replicates on three consecutive days. Acceptable criteria for
recision and accuracy of LLOQ were relative standard deviation
RSD) not exceeding 20% and relative error (RE) within ±20%. The
ignal-to-noise ratio should be larger than 5.
The calibration curves were plotted in duplicate on three con-
ecutive days to determine linearity. Linearity was assessed by
eighted (1/x2) least-squares analysis of six different calibration
urves. The coefﬁcient of the correlation should exceed 0.99. The
eviations of the measured concentrations should be within ±15%
f thenominal concentrations except for LLOQ, atwhich adeviation
f ±20% is allowed.
QC samples at three levels (low, medium, and high) in six repli-
ateswere analyzed on three validation days to assess the accuracy
nd precision. Accuracy, expressed as RE (%) should be withiniomedical Analysis 85 (2013) 118–122
±15%, and intra- and inter-day precision, expressed as RSD (%), was
required not to exceed 15%.
The extraction recovery was determined by comparing the
mean peak areas of six extracted samples at low, medium, and
high QC concentrations with the mean peak areas of spike-after-
extraction samples.
Blank plasma samples from six sourceswere extracted and then
spiked with analyte and IS to assess the matrix effect. The corre-
sponding peak area ratios of the analyte to IS in spiked plasma
post-extraction (A) at low and high QC levels were then compared
with those of the corresponding standard samples (B) at equiva-
lent concentrations. The ratio (A/B×100%) is deﬁned as the matrix
effect. Avalueof 100% is indicativeofnomatrix effect, a value>100%
suggests ionization enhancement and a value <100% suggests ion-
ization suppression.
The stability of low and high QC samples (n=3) in three com-
plete freeze/thaw cycles (−80 to 22 ◦C), long-term sample storage
(−80 ◦C for 30days), andbench-top (23 ◦C for 2h)was assessed. The
ready to-injection stability of extracted samples in the autosampler
rack at 4 ◦C for 24h was also evaluated.
2.7. Clinical study and therapeutic drug monitoring
Eight patientswith leukemia (<5 years old)were enrolled to this
study. The study protocolwas approved by the Ethics Committee of
the First Afﬁliated Hospital of Nanchang University and conducted
in accordance with the Declaration of Helsinki and the principles
of GoodClinical Practice.Written informed consentswere obtained
from all subjects prior to the study. The patient was intravenously
infusedwith ara-C (2 g/m2)within 2h every day and this treatment
continued for 5 days. Serial blood samples (1mL) were obtained at
5, 30min and 1, 1.5, 2h during the period of infusion, 30min and 1,
2, 3, 4, 6h after infusion. All plasma samples were placed into hep-
arinized tubes containing THU (ﬁnal concentration 0.1mM). After
centrifugation at 800× g and 4 ◦C for 10min, plasma was collected
and frozen at −80 ◦C until analysis.
3. Result and discussion
3.1. Method development
A HPLC–MS/MS method to determine ara-U and ara-C simulta-
neously has been attempted. But it was difﬁcult to extract ara-U
and ara-C at the same time from the human plasma. Therefore, two
HPLC–MS/MS methods were developed to determine the concen-
tration of ara-U and ara-C respectively.
Because ara-U has two nitrogen atoms in the structure, it has
a stronger mass response in the positive ionization mode than the
negative mode. Therefore, the positive MRM mode was selected
for the quantiﬁcation of ara-U. The product ions of the [M+H]+ of
ara-U was dependent on the collision voltage. The major fragment
ion m/z 113.2 was formed at higher collision voltage, and the most
abundant ion m/z 215.4 was formed at lower collision voltage. The
transition of m/z 245.1→113.2 gave a higher signal-to-noise (S/N)
ratio and better response than that ofm/z 245.1→215.4 during the
analysis of the spiked plasma samples. As a result, the transition of
m/z 245.1→113.2 was selected for MRM analysis of ara-U (Fig. 1).
In the same way, the transition m/z 137.9→120.9 was selected for
the analysis of isoniazid with CE of 15eV.
Because ara-U and isoniazid were hydrophilic compounds, the
protein precipitation pretreatment was applied to prepare the
plasma sample. During our preliminary exploration, acetonitrile as
the precipitation solution can provide higher extraction recovery
and cleaner sample than methanol, thus reduced the background
noise and increased the sensitivity.
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Fig. 2. Representative MRM chromatograms of isoniazid (I), ara-U (II) in human
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Table 1
Precision and accuracy of ara-U and ara-C in humanplasma (in three validationdays,
six replicates at different concentration levels per day).
Concentration (ng/mL) RSD (%) Relative error (%)
Added Found (mean) Intra-day Inter-day
ara-U
2 2.2 8.2 7.7 10.0
3500 3370.1 7.3 6.3 −3.7
6000 6273.5 6.1 7.0 4.6
ara-C
10 11.2 6.7 7.3 12.0lasma: (A) a blank human plasma sample; (B) a blank plasma sample spiked with
ra-U (1ng/mL) and isoniazid (4000.0ng/mL); (C) a plasma sample after an infusion
f ara-C at 2 g/m2 to a patient with leukemia.
The method for the determination of ara-C in human plasma
as developed according to the publications [10–15].
.2. Method validation.2.1. Selectivity
Figs. 2 and3 showthe typical chromatogramsof ablank, a spiked
lasma sample with ara-U (1ng/mL), ara-C (5ng/mL) and the
ig. 3. Representative MRM chromatograms of ara-C (I), lamivudine (II) in human
lasma: (A) a blank human plasma sample; (B) a blank plasma sample spiked with
ra-C (5.0ng/mL) and lamivudine (1000.0ng/mL); (C) a plasma sample after an
nfusion of ara-C at 2 g/m2 to a patient with leukemia.2500 2670.2 9.1 7.1 6.8
4000 4230.1 5.8 8.2 5.6
internal standard, a plasma sample fromapatient after the infusion
of ara-C. No interference from the endogenous compound with the
analytes and the internal standard was found.
3.2.2. Linearity and LLOQ
The linear regressions of the peak area ratios versus concentra-
tion were ﬁtted over the concentration range of 1.0–7000.0ng/mL
for ara-U and 5.0–5000.0ng/mL for ara-C. The typical equation of
the calibrationcurveswasas follows: ara-U:y=0.08102+0.00451x,
r=0.9908; ara-C: y=0.09482+0.00602x, r=0.9919, where y rep-
resents the peak area ratio of analytes to IS and x represents the
concentration of the analytes in plasma. The correlation coefﬁcient
(r) exceeded 0.99, showing a good linearity among the concentra-
tion range.
The lower limit of quantiﬁcation (LLOQ) was 1.0ng/mL for ara-
U and 5.0ng/mL for ara-C. The intra- and inter-RSD were both less
than 15% and the RE were within ±9.5% at LLOQ level, which were
within the accepted limits.
3.2.3. Matrix effect and recovery
The matrix effects calculated were in the range of 91.5–108.2%.
Therefore, ion suppression or enhancement from human plasma
was negligible under the current conditions.
Table 2
Stability data of ara-U and ara-C in human plasma under different conditions.
Concentration (ng/mL) RSD (%) RE (%)
Added Found (mean)
Bench-top (23 ◦C for 2h)
ara-U
2.0 2.3 9.3 13.4
6000 6178.8 4.5 3.1
ara-C
10.0 10.9 8.3 9.1
4000.0 4126.8 6.1 3.2
Three freeze/thaw cycles (−80 to 22 ◦C)
ara-U
2.0 2.1 11.5 4.7
6000 6258.3 7.9 4.3
ara-C
10.0 10.7 7.4 6.9
4000.0 3845.7 5.2 −3.9
Autosampler rack at 4 ◦C for 24h
ara-U
2.0 1.9 9.4 −4.4
6000 5812.1 5.7 −3.1
ara-C
10.0 9.4 6.8 −6.1
4000.0 4201.1 4.6 5.0
Freezing at −80 ◦C for 30 days
ara-U
2.0 2.2 8.9 10.2
6000 5835.6 6.4 −2.7
ara-C
10.0 10.5 9.0 4.9
4000.0 4109.3 7.5 2.7
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[ig. 4. (a) Plasmaconcentration–timeproﬁles of ara-Uandara-C; (b) the ratio of ara-
/ara-C after an intravenous infusion of ara-C at 2 g/m2 to a patient with leukemia.
The mean extraction recoveries were 80.3±5.3%, 78.9±4.6%
nd 78.5±4.6% for ara-U at 2.0, 3500.0, and 6000.0ng/mL, and
7.3±3.9%, 93.1±5.1% and 86.1±4.0% for ara-C at 10.0, 2500.0,
nd 4000.0ng/mL, respectively. Themean recovery of isoniazid and
amivudine were 85.3±4.1% and 93.4±4.7%, respectively.
.2.4. Precision and accuracy
Table 1 summarizes the intra- and inter-day precision and accu-
acy for the analytes in QC samples. The intra- and inter-day RSD
ere below 9.1%, and the relative errors were from −3.7% to 12.0%.
ll the values were within the accepted range and the method was
ccurate and precise.
.2.5. Stability
Stability results in Table 2 demonstrated that ara-U and ara-C
as stable in human plasma under the indicated conditions.
.3. Clinical study and therapeutic drug monitoringThis validated method was successfully applied to the disposi-
ion characteristics and the therapeutic drug monitoring of ara-U
fter ara-C was infused to the patient with leukemia. The con-
entration of ara-C was also determined (unpublished data). The
[iomedical Analysis 85 (2013) 118–122
typical plasma concentration–time proﬁle of ara-U was shown in
Fig. 3a. The ratio of ara-U/ara-C was shown in Fig. 3b. It can be
seen from Fig. 3b that the concentration of ara-U was much higher
than ara-C. The high level of ara-U would persist throughout the
multiple-dose treatment with HiDAC, and it was beneﬁcial to the
therapeutic effect of ara-C (Fig. 4) [3].
4. Conclusion
The present study developed and validated a facile, speciﬁc, and
sensitive HPLC–MS/MS method for the determination of ara-U in
humanplasma. The LLOQwas 1ng/mL,whichwas sensitive enough
to determine the low concentration of ara-U in human plasma. The
protein precipitation pretreatment was very convenient and pro-
videdhigh recovery (about 80%). Thismethodhas been successfully
applied to the disposition characteristics and the therapeutic drug
monitoring of ara-U after ara-C was infused to the patient with
leukemia.
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